サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1435018

抗体薬物複合体の受託製造市場：リンカー、条件、最終用途別-2024-2030年の世界予測

Antibody Drug Conjugates Contract Manufacturing Market by Linker (Cleavable, Non-cleavable), Condition (Breast Cancer, Lymphoma, Myeloma), End Use - Global Forecast 2024-2030
出版日: | 発行: 360iResearch | ページ情報: 英文 193 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
抗体薬物複合体の受託製造市場：リンカー、条件、最終用途別-2024-2030年の世界予測
出版日: 2024年01月15日
発行: 360iResearch
ページ情報: 英文 193 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

抗体薬物複合体の受託製造市場規模は2023年に118億8,000万米ドルと推計され、2024年には130億6,000万米ドルに達し、CAGR 11.82%で2030年には259億9,000万米ドルに達すると予測されます。

抗体薬物複合体の受託製造の世界市場

主な市場の統計
基準年[2023］ 118億8,000万米ドル
予測年[2024］ 130億6,000万米ドル
予測年 [2030] 259億9,000万米ドル
CAGR（%） 11.82%
抗体薬物複合体の受託製造 Market-IMG1

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは抗体薬物複合体の受託製造市場を評価する上で極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、抗体薬物複合体の受託製造市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された累積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1-市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2-市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3-市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4-競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5-製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1-抗体薬物複合体の受託製造市場の市場規模および予測は？

2-抗体薬物複合体の受託製造市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3-抗体薬物複合体の受託製造市場における技術動向と規制の枠組みは？

4-抗体薬物複合体の受託製造市場における主要ベンダーの市場シェアは？

5-抗体薬物複合体の受託製造市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • バイオ医薬品企業によるアウトソーシングの増加
      • CMOの数の急増と継続的な研究開発活動
      • 慢性疾患の有病率が高い中、ADCの需要が増大
    • 抑制要因
      • 抗体薬物複合体の生産施設の設置に高額な費用がかかる
    • 機会
      • 規制当局からのADC承認の急増
      • 先端製造技術への投資拡大
    • 課題
      • CMOに対する厳しい規制要件
  • 市場セグメンテーション分析
  • 市場動向分析
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み

第6章 抗体薬物複合体の受託製造市場byリンカー

  • 切断可能
  • 非切断性

第7章 抗体薬物複合体の受託製造市場条件別

  • 乳がん
  • リンパ腫
  • 骨髄腫

第8章 抗体薬物複合体の受託製造市場：最終用途別

  • 臨床試験
  • 骨髄腫の治療

第9章 南北アメリカの抗体薬物複合体の受託製造市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第10章 アジア太平洋地域の抗体薬物複合体の受託製造市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第11章 欧州・中東・アフリカの抗体薬物複合体の受託製造市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第12章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析：主要企業別
  • 競合シナリオ主要企業別の分析

第13章 競争力のあるポートフォリオ

  • 主要な企業プロファイル
    • AbbVie Inc.
    • ADC Therapeutics SA.
    • AstraZeneca PLC
    • Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
    • Axplora
    • Catalent, Inc.
    • Creative Biolabs
    • Daiichi Sankyo
    • EirGenix, Inc.
    • Gilead Sciences
    • GlaxoSmithKline PLC
    • ImmunoGen, Inc.
    • Merck KgaA
    • Mersana Therapeutics
    • MicroBiopharm Japan Co., Ltd.
    • Pfizer Inc.
    • Pierre Fabre S.A
    • Piramal Pharma Solutions
    • Recipharm AB
    • Regeneron Pharmaceuticals, Inc.
    • Samsung Biologics
    • Sanofi
    • Sartorius AG
  • 主要な製品ポートフォリオ

第14章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET RESEARCH PROCESS
  • FIGURE 2. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2023 VS 2030
  • FIGURE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET DYNAMICS
  • FIGURE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2030 (%)
  • FIGURE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2030 (%)
  • FIGURE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2030 (%)
  • FIGURE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 14. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 16. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 18. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
  • FIGURE 22. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023

LIST OF TABLES

  • TABLE 1. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 6. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY NON-CLEAVABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 9. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 13. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CLINICAL TRIAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY MYELOMA TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 16. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 17. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 18. AMERICAS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 19. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 20. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 21. ARGENTINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 22. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 23. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 24. BRAZIL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 25. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 26. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 27. CANADA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 28. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 29. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 30. MEXICO ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 31. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 32. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 33. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 34. UNITED STATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 35. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 36. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 37. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 38. ASIA-PACIFIC ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 39. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 40. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 41. AUSTRALIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 42. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 43. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 44. CHINA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 45. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 46. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 47. INDIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 48. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 49. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 50. INDONESIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 51. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 52. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 53. JAPAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 54. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 55. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 56. MALAYSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 57. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 58. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 59. PHILIPPINES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 60. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 61. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 62. SINGAPORE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 63. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 64. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 65. SOUTH KOREA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 66. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 67. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 68. TAIWAN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 69. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 70. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 71. THAILAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 72. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 73. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 74. VIETNAM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 75. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 76. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 80. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 81. DENMARK ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 82. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 83. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 84. EGYPT ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 85. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 86. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 87. FINLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 88. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 89. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 90. FRANCE ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 91. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 92. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 93. GERMANY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 94. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 95. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 96. ISRAEL ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 97. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 98. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 99. ITALY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 100. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 101. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 102. NETHERLANDS ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 103. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 104. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 105. NIGERIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 106. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 107. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 108. NORWAY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 109. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 110. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 111. POLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 112. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 113. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 114. QATAR ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 115. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 116. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 117. RUSSIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 118. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 119. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 120. SAUDI ARABIA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 121. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 122. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH AFRICA ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 124. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 125. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 126. SPAIN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 127. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 128. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 129. SWEDEN ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 130. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 131. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 132. SWITZERLAND ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 133. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 134. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 135. TURKEY ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 136. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 137. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 138. UNITED ARAB EMIRATES ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 139. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY LINKER, 2018-2030 (USD MILLION)
  • TABLE 140. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY CONDITION, 2018-2030 (USD MILLION)
  • TABLE 141. UNITED KINGDOM ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SIZE, BY END USE, 2018-2030 (USD MILLION)
  • TABLE 142. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET, FPNV POSITIONING MATRIX, 2023
  • TABLE 143. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 144. ANTIBODY DRUG CONJUGATES CONTRACT MANUFACTURING MARKET LICENSE & PRICING
目次
Product Code: MRR-B16853777721

[193 Pages Report] The Antibody Drug Conjugates Contract Manufacturing Market size was estimated at USD 11.88 billion in 2023 and expected to reach USD 13.06 billion in 2024, at a CAGR 11.82% to reach USD 25.99 billion by 2030.

Global Antibody Drug Conjugates Contract Manufacturing Market

KEY MARKET STATISTICS
Base Year [2023] USD 11.88 billion
Estimated Year [2024] USD 13.06 billion
Forecast Year [2030] USD 25.99 billion
CAGR (%) 11.82%
Antibody Drug Conjugates Contract Manufacturing Market - IMG1

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Antibody Drug Conjugates Contract Manufacturing Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Drug Conjugates Contract Manufacturing Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Antibody Drug Conjugates Contract Manufacturing Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., ADC Therapeutics SA., AstraZeneca PLC, Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories, Axplora, Catalent, Inc., Creative Biolabs, Daiichi Sankyo, EirGenix, Inc., Gilead Sciences, GlaxoSmithKline PLC, ImmunoGen, Inc., Merck KgaA, Mersana Therapeutics, MicroBiopharm Japan Co., Ltd., Pfizer Inc., Pierre Fabre S.A, Piramal Pharma Solutions, Recipharm AB, Regeneron Pharmaceuticals, Inc., Samsung Biologics, Sanofi, and Sartorius AG.

Market Segmentation & Coverage

This research report categorizes the Antibody Drug Conjugates Contract Manufacturing Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Linker
    • Cleavable
    • Non-cleavable
  • Condition
    • Breast Cancer
    • Lymphoma
    • Myeloma
  • End Use
    • Clinical Trial
    • Myeloma Treatment
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the Antibody Drug Conjugates Contract Manufacturing Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Drug Conjugates Contract Manufacturing Market?

3. What are the technology trends and regulatory frameworks in the Antibody Drug Conjugates Contract Manufacturing Market?

4. What is the market share of the leading vendors in the Antibody Drug Conjugates Contract Manufacturing Market?

5. Which modes and strategic moves are suitable for entering the Antibody Drug Conjugates Contract Manufacturing Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Antibody Drug Conjugates Contract Manufacturing Market, by Region

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing outsourcing by biopharmaceutical companies
      • 5.1.1.2. Surging number of CMOs and ongoing R&D activities
      • 5.1.1.3. Growing demand for ADC amid high prevalence of chronic disease
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of setting up a production facility for antibody-drug conjugates
    • 5.1.3. Opportunities
      • 5.1.3.1. Surge in ADC approvals from regulatory bodies
      • 5.1.3.2. Expanding investments in advanced manufacturing technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Stringent regulatory requirements for CMOs
  • 5.2. Market Segmentation Analysis
  • 5.3. Market Trend Analysis
  • 5.4. Cumulative Impact of High Inflation
  • 5.5. Porter's Five Forces Analysis
    • 5.5.1. Threat of New Entrants
    • 5.5.2. Threat of Substitutes
    • 5.5.3. Bargaining Power of Customers
    • 5.5.4. Bargaining Power of Suppliers
    • 5.5.5. Industry Rivalry
  • 5.6. Value Chain & Critical Path Analysis
  • 5.7. Regulatory Framework

6. Antibody Drug Conjugates Contract Manufacturing Market, by Linker

  • 6.1. Introduction
  • 6.2. Cleavable
  • 6.3. Non-cleavable

7. Antibody Drug Conjugates Contract Manufacturing Market, by Condition

  • 7.1. Introduction
  • 7.2. Breast Cancer
  • 7.3. Lymphoma
  • 7.4. Myeloma

8. Antibody Drug Conjugates Contract Manufacturing Market, by End Use

  • 8.1. Introduction
  • 8.2. Clinical Trial
  • 8.3. Myeloma Treatment

9. Americas Antibody Drug Conjugates Contract Manufacturing Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Antibody Drug Conjugates Contract Manufacturing Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Antibody Drug Conjugates Contract Manufacturing Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. FPNV Positioning Matrix
  • 12.2. Market Share Analysis, By Key Player
  • 12.3. Competitive Scenario Analysis, By Key Player

13. Competitive Portfolio

  • 13.1. Key Company Profiles
    • 13.1.1. AbbVie Inc.
    • 13.1.2. ADC Therapeutics SA.
    • 13.1.3. AstraZeneca PLC
    • 13.1.4. Aurigene Pharmaceutical Services Ltd. by Dr. Reddy's Laboratories
    • 13.1.5. Axplora
    • 13.1.6. Catalent, Inc.
    • 13.1.7. Creative Biolabs
    • 13.1.8. Daiichi Sankyo
    • 13.1.9. EirGenix, Inc.
    • 13.1.10. Gilead Sciences
    • 13.1.11. GlaxoSmithKline PLC
    • 13.1.12. ImmunoGen, Inc.
    • 13.1.13. Merck KgaA
    • 13.1.14. Mersana Therapeutics
    • 13.1.15. MicroBiopharm Japan Co., Ltd.
    • 13.1.16. Pfizer Inc.
    • 13.1.17. Pierre Fabre S.A
    • 13.1.18. Piramal Pharma Solutions
    • 13.1.19. Recipharm AB
    • 13.1.20. Regeneron Pharmaceuticals, Inc.
    • 13.1.21. Samsung Biologics
    • 13.1.22. Sanofi
    • 13.1.23. Sartorius AG
  • 13.2. Key Product Portfolio

14. Appendix

  • 14.1. Discussion Guide
  • 14.2. License & Pricing